Plasminogen activator inhibitor 1 and visceral obesity during pronounced weight loss after bariatric surgery

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 22, Issue 4, 2012, Pages 340-346

  Tschoner, A ^a   Sturm, W ^a   Engl, J ^a   Kaser, S ^a   Laimer, M ^a   Laimer, E ^a   Klaus, A ^a   Patsch, J R ^a   Ebenbichler, C F ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Bariatric surgery; Fibrinolysis; Plasminogen activator inhibitor 1; Visceral obesity; Weight loss

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERPINE1 PROTEIN, HUMAN;

ABDOMINAL OBESITY; ADULT; ARTICLE; BARIATRIC SURGERY; BLOOD; FEMALE; HUMAN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROSPECTIVE STUDY; STATISTICAL MODEL; WEIGHT REDUCTION;

ADULT; BARIATRIC SURGERY; CHOLESTEROL, LDL; FEMALE; HUMANS; LINEAR MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY, ABDOMINAL; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSPECTIVE STUDIES; WEIGHT LOSS;

EID: 84858446850     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2010.07.009     Document Type: Article

References (30)

1. Saksela O., Rifkin D.B. Cell-associated plasminogen activation: regulation and physiological functions. Annu Rev Cell Biol 1988, 4:93-126.
2. Alessi M.C., Juhan-Vague I. Metabolic syndrome, haemostasis and thrombosis. Thromb Haemost 2008, 99:995-1000.
3. De Taeye B., Smith L.H., Vaughan D.E. Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease. Curr Opin Pharmacol 2005, 5:149-154.
4. Van Gaal L.F., Mertens I.L., De Block C.E. Mechanisms linking obesity with cardiovascular disease. Nature 2006, 444:875-880.
5. Bastelica D., Morange P., Berthet B., Borghi H., Lacroix O., Grino M., et al. Stromal cells are the main plasminogen activator inhibitor-1-producing cells in human fat: evidence of differences between visceral and subcutaneous deposits. Arterioscler Thromb Vasc Biol 2002, 22:173-178.
6. Alessi M.C., Bastelica D., Morange P., Berthet B., Leduc I., Verdier M., et al. Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes 2000, 49:1374-1380.
7. Eriksson P., Van Harmelen V., Hoffstedt J., Lundquist P., Vidal H., Stemme V., et al. Regional variation in plasminogen activator inhibitor-1 expression in adipose tissue from obese individuals. Thromb Haemost 2000, 83:545-548.
8. Buchwald H., Avidor Y., Braunwald E., Jensen M.D., Pories W., Fahrbach K., et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004, 292:1724-1737.
9. Nehoda H., Weiss H., Labeck B., Hourmont K., Lanthaler M., Oberwalder M., et al. Results and complications after adjustable gastric banding in a series of 250 patients. Am J Surg 2001, 181:12-15.
10. Alberti K.G., Zimmet P., Shaw J. Metabolic syndrome - a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med 2006, 23:469-480.
11. Pontiroli A.E., Pizzocri P., Giacomelli M., Marchi M., Vedani P., Cucchi E., et al. Ultrasound measurement of visceral and subcutaneous fat in morbidly obese patients before and after laparoscopic adjustable gastric banding: comparison with computerized tomography and with anthropometric measurements. Obes Surg 2002, 12:648-651.
12. Uzun H., Zengin K., Taskin M., Aydin S., Simsek G., Dariyerli N. Changes in leptin, plasminogen activator factor and oxidative stress in morbidly obese patients following open and laparoscopic Swedish adjustable gastric banding. Obes Surg 2004, 14:659-665.
13. Vazquez L.A., Pazos F., Berrazueta J.R., Fernandez-Escalante C., Garcia-Unzueta M.T., Freijanes J., et al. Effects of changes in body weight and insulin resistance on inflammation and endothelial function in morbid obesity after bariatric surgery. J Clin Endocrinol Metab 2005, 90:316-322.
14. Kockx M., Leenen R., Seidell J., Princen H.M., Kooistra T. Relationship between visceral fat and PAI-1 in overweight men and women before and after weight loss. Thromb Haemost 1999, 82:1490-1496.
15. Halleux C.M., Declerck P.J., Tran S.L., Detry R., Brichard S.M. Hormonal control of plasminogen activator inhibitor-1 gene expression and production in human adipose tissue: stimulation by glucocorticoids and inhibition by catecholamines. J Clin Endocrinol Metab 1999, 84:4097-4105.
16. Alessi M.C., Peiretti F., Morange P., Henry M., Nalbone G., Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 1997, 46:860-867.
17. He G., Pedersen S.B., Bruun J.M., Lihn A.S., Jensen P.F., Richelsen B. Differences in plasminogen activator inhibitor 1 in subcutaneous versus omental adipose tissue in non-obese and obese subjects. Horm Metab Res 2003, 35:178-182.
18. Polac I., Cierniewska-Cieslak A., Stachowiak G., Pertynski T., Cierniewski C.S. Similar PAI-1 expression in visceral and subcutaneous fat of postmenopausal women. Thromb Res 2001, 102:397-405.
19. Lindeman J.H., Pijl H., Toet K., Eilers P.H., van Ramshorst B., Buijs M.M., et al. Human visceral adipose tissue and the plasminogen activator inhibitor type 1. Int J Obesity 2005, 2007(31):1671-1679.
20. Gottschling-Zeller H., Birgel M., Rohrig K., Hauner H. Effect of tumor necrosis factor alpha and transforming growth factor beta 1 on plasminogen activator inhibitor-1 secretion from subcutaneous and omental human fat cells in suspension culture. Metabolism 2000, 49:666-671.
21. Rega G., Kaun C., Weiss T.W., Demyanets S., Zorn G., Kastl S.P., et al. Inflammatory cytokines interleukin-6 and oncostatin m induce plasminogen activator inhibitor-1 in human adipose tissue. Circulation 2005, 111:1938-1945.
22. Curat C.A., Wegner V., Sengenes C., Miranville A., Tonus C., Busse R., et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006, 49:744-747.
23. Cancello R., Tordjman J., Poitou C., Guilhem G., Bouillot J.L., Hugol D., et al. Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity. Diabetes 2006, 55:1554-1561.
24. Cancello R., Henegar C., Viguerie N., Taleb S., Poitou C., Rouault C., et al. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes 2005, 54:2277-2286.
25. Wang L., Rockwood J., Zak D., Devaraj S., Jialal I. Simvastatin reduces circulating plasminogen activator inhibitor 1 activity in volunteers with the metabolic syndrome. Metab Syndr Relat Disord 2008, 6:149-152.
26. Chen C.L., Liu I.H., Fliesler S.J., Han X., Huang S.S., Huang J.S. Cholesterol suppresses cellular TGF-beta responsiveness: implications in atherogenesis. J Cell Sci 2007, 120:3509-3521.
27. Eliasson M., Jansson J.H., Nilsson P., Asplund K. Increased levels of tissue plasminogen activator antigen in essential hypertension. A population-based study in Sweden. J Hypertens 1997, 15:349-356.
28. Wall U., Jern C., Bergbrant A., Jern S. Enhanced levels of tissue-type plasminogen activator in borderline hypertension. Hypertension 1995, 26:796-800.
29. Wang T.J., Gona P., Larson M.G., Levy D., Benjamin E.J., Tofler G.H., et al. Multiple biomarkers and the risk of incident hypertension. Hypertension 2007, 49:432-438.
30. Jeng J.R., Sheu W.H., Jeng C.Y., Huang S.H., Shieh S.M. Impaired fibrinolysis and insulin resistance in patients with hypertension. Am J Hypertens 1996, 9:484-490.